
Join to view full profile
9701 Richmond AveSte 122Houston, TX 77042
Phone+1 713-781-6200
Fax+1 713-781-6206
Dr. Delpassand is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Baylor College of MedicineResidency, Pathology-Anatomic and Clinical, 1990 - 1991
Baylor College of MedicineResidency, Nuclear Medicine, 1988 - 1990
Tehran University of Medical Sciences School of MedicineClass of 1982
Certifications & Licensure
TX State Medical License 1990 - 2027
OK State Medical License 1988 - 1992
American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer
- Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
- 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Start of enrollment: 2010 Oct 27
Publications & Presentations
PubMed
- Tumor and Organ Dose Estimates fromLu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.Zachary Ells, Catherine Meyer, Karam Masri, Marc Ryhiner, David Sennung
Journal of Nuclear Medicine. 2026-10-01 - 2 citationsNANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.Hagen Kennecke, Ebrahim Delpassand, Seth Felder, Ferga Gleeson, Julie Hallet
Endocrine-Related Cancer. 2026-02-01 - 2 citationsA trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.Devalingam Mahalingam, Taofeek K Owonikoko, Ebrahim Delpassand, Mary F Mulcahy, Aparna Kalyan
Cancer. 2025-01-01
Press Mentions
Right to Try Is Unleashing the Future of MedicineSeptember 13th, 2022
Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma MultiformeJuly 8th, 2021
RadioMedix & Curium Announce Detectnetᵀᴹ (Copper Cu 64 Dotatate Injection) Inclusion on NCCN Guidelines®May 5th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: